North Chicago, IL – February 2026 – AbbVie Inc. reported a strong full-year financial performance in 2025, underscoring the successful execution of its multi-year portfolio transformation strategy and the accelerating contribution of next-generation growth brands. The results highlight AbbVie’s evolution beyond legacy dependence toward a diversified, innovation-driven biopharmaceutical leader with durable positions across immunology, neuroscience, and emerging therapeutic areas.
“2025 marked a pivotal year for AbbVie as our next-generation platforms continued to scale and validate the strength of our long-term strategy,” said Richard A. Gonzalez, Chairman and Chief Executive Officer, AbbVie.
“The performance of SKYRIZI and RINVOQ demonstrates our ability to translate deep immunology expertise into sustained growth, while our expanding neuroscience and oncology portfolios reinforce the durability and breadth of our business.”
2025 Financial and Operational Performance
For the full year 2025, AbbVie delivered approximately $61.2 billion in total net revenues, reflecting solid year-over-year growth driven primarily by expansion in core growth franchises. Performance exceeded internal expectations and demonstrated the company’s ability to scale new platforms while maintaining operational discipline.
Adjusted earnings performance remained resilient, supported by strong gross margins, disciplined cost management, and sustained investment in research and development.
“Our 2025 results reflect a balance of strong execution today and disciplined investment for the future,” Gonzalez added.
“We continue to allocate capital toward innovation that expands our therapeutic reach while maintaining operational excellence across the organization.”
Immunology: Core Growth Engine of the Portfolio
AbbVie’s immunology franchise remained the primary driver of growth in 2025 and now represents the strategic center of the company’s long-term value creation.
SKYRIZI® (risankizumab)
SKYRIZI delivered strong double-digit growth in 2025, supported by expanding adoption across dermatology and gastroenterology. Continued uptake in psoriasis and increasing penetration in inflammatory bowel disease reinforced SKYRIZI’s role as a cornerstone biologic across multiple chronic inflammatory conditions.
“SKYRIZI exemplifies how AbbVie is redefining standards of care in immune-mediated diseases,” said Dr. Roopal Thakkar, Executive Vice President, Research & Development and Chief Scientific Officer, AbbVie.
“Its performance reflects not only clinical differentiation, but also the depth of our translational science and our commitment to delivering durable benefits for patients across multiple indications.”
RINVOQ® (upadacitinib)
RINVOQ maintained a rapid growth trajectory in 2025, supported by broadening utilization across rheumatologic, dermatologic, and gastrointestinal indications. Ongoing regulatory progress and label expansion continue to strengthen RINVOQ’s position as a flagship oral therapy within AbbVie’s immunology portfolio.
“RINVOQ continues to demonstrate the power of precision immunology,” Dr. Thakkar added.
“Its expanding clinical profile reinforces our strategy of developing therapies that are both mechanistically differentiated and scalable across large patient populations.”
Together, SKYRIZI and RINVOQ form the foundation of AbbVie’s post-Humira growth strategy, with combined revenues continuing to scale and providing long-term visibility across immunology markets.
Legacy Transition and Portfolio Balance
Humira
While Humira experienced continued decline in 2025 following biosimilar competition, the product remained a meaningful contributor to overall revenues. AbbVie managed the transition through targeted pricing, formulary strategies, and geographic optimization, allowing for a controlled and predictable evolution.
“Our Humira transition has progressed in line with expectations and reflects years of deliberate planning,” Gonzalez noted.
“Importantly, the strength of our growth portfolio has enabled us to navigate this transition from a position of confidence.”
Neuroscience: Expanding a Second Growth Pillar
AbbVie’s neuroscience portfolio delivered strong performance in 2025, reinforcing the therapeutic area as a second major growth pillar alongside immunology.
Key brands including Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta demonstrated sustained demand across psychiatry, migraine, and movement disorder indications.
“Neuroscience remains a high-conviction area for AbbVie,” said Dr. Thakkar.
“We are building a differentiated portfolio that addresses chronic, high-impact neurological conditions while advancing next-generation assets that extend our leadership well into the future.”
Oncology and Emerging Therapeutic Areas
AbbVie continued to advance its oncology portfolio, progressing assets across hematologic malignancies and solid tumors. The company also expanded investment in emerging modalities, including bispecific antibodies, cell therapies, and targeted precision platforms.
“Our oncology and emerging pipeline reflects a deliberate focus on science-driven differentiation,” Dr. Thakkar said.
“We are advancing programs that have the potential to redefine treatment paradigms in areas of high unmet need.”
Strategic Outlook
Looking ahead, AbbVie’s strategy is anchored on:
- Sustained immunology growth, driven by global expansion and indication breadth for SKYRIZI and RINVOQ
- Scaling neuroscience leadership, supported by durable brands and pipeline extensions
- Portfolio diversification, through oncology innovation and emerging therapeutic platforms
- Long-term R&D investment, aligned with disciplined execution
“AbbVie enters the next phase of growth with a diversified portfolio, a deep pipeline, and a clear strategic vision,” Gonzalez concluded.
“Our focus remains on delivering meaningful innovation for patients while building a resilient, high-performing biopharmaceutical company for the long term.”
About AbbVie
AbbVie is a global biopharmaceutical company committed to discovering and delivering innovative medicines that address serious health challenges. With leadership positions in immunology, neuroscience, oncology, and emerging therapeutic areas, AbbVie is focused on improving outcomes for patients worldwide through science-driven innovation.
By